pharma news

News

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.

News

ESC26: AZ's relaxin agonist shows promise in heart failure

An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with heart failure.

News

FDA clears Takeda, Protagonist's first-in-class PV drug

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

News

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.

News

Acquisitive Lilly offers $2.88bn for Merida Bio

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.

News

ESC26: Heart attack reclassification rights gender imbalance

New definitions of myocardial infarction released at ESC 2026 recognise that there are different causes - and could lead to better treatment of women.

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

ESC26: AZ's relaxin agonist shows promise in heart failure

FDA clears Takeda, Protagonist's first-in-class PV drug

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

Acquisitive Lilly offers $2.88bn for Merida Bio

ESC26: Heart attack reclassification rights gender imbalance

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks